ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 102 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.23 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $111,733 | -44.3% | 21,042 | 0.0% | 0.00% | – |
| Q2 2023 | $200,530 | +11.2% | 21,042 | +28.4% | 0.00% | – |
| Q1 2023 | $180,312 | -28.6% | 16,392 | -4.0% | 0.00% | – |
| Q4 2022 | $252,606 | -7.1% | 17,068 | +19.9% | 0.00% | – |
| Q3 2022 | $271,954 | -9.8% | 14,231 | +0.6% | 0.00% | – |
| Q2 2022 | $301,579 | +28.1% | 14,152 | +15.8% | 0.00% | – |
| Q1 2022 | $235,376 | -26.0% | 12,221 | -20.8% | 0.00% | – |
| Q4 2021 | $318,000 | -10.7% | 15,428 | +3.5% | 0.00% | – |
| Q3 2021 | $356,000 | -19.1% | 14,911 | -7.5% | 0.00% | – |
| Q2 2021 | $440,000 | +17.3% | 16,119 | +24.2% | 0.00% | – |
| Q1 2021 | $375,000 | +10.3% | 12,975 | +7.3% | 0.00% | – |
| Q4 2020 | $340,000 | +18.9% | 12,087 | +23.6% | 0.00% | – |
| Q3 2020 | $286,000 | – | 9,776 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 10,542,790 | $314,175,000 | 35.62% |
| Bain Capital Life Sciences Investors, LLC | 3,979,292 | $118,583,000 | 20.06% |
| Omega Fund Management, LLC | 844,680 | $25,171,000 | 10.42% |
| Vivo Capital, LLC | 1,686,527 | $50,259,000 | 4.55% |
| Orbimed Advisors | 4,673,850 | $139,281,000 | 2.34% |
| RA Capital Management | 1,165,184 | $34,722,000 | 1.10% |
| Polar Capital LLP | 375,000 | $11,175,000 | 0.12% |
| CAAS CAPITAL MANAGEMENT LP | 22,413 | $668,000 | 0.07% |
| FMR LLC | 5,713,343 | $170,258,000 | 0.02% |
| Laurion Capital Management LP | 50,000 | $1,490,000 | 0.02% |